Feed BMRN
BM

BioMarin Pharmaceutical

BMRN · NASDAQ

$60.26 -2.02% (-$1.24)
1M -7.70%
Market Cap $11.9B
P/E Ratio 162.50x
Div. Yield -
ROE 1.18%

Bulios Fair Price

$77.04

27.8% upside

Trenutna cena

$60.26

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BMRN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
4/9
Valuation
39 /100
Fair
P/S 3.48x
P/E 162.50x
P/B 1.88x
Growth
94 /100
Growing
FCF growth 136.30%
EPS growth 33.89%
Book val. growth 9.76%
Profitability
64 /100
Moderate
Op. margin 8.02%
Gross margin 75.55%
FCF margin 21.51%
Quality
7 /100
Poor
ROA 0.62%
ROIC 1.25%
Asset turnover 0.29x
Debt
43 /100
Moderate
Int. coverage 2.78x
Debt/Equity 0.66x
Net debt/EBITDA 8.63x
Stability
42 /100
Moderate
EPS volatility 89.43%
Beta 0.24x
Profitable years 4

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BMRN
Online

O podjetju

BioMarin Pharmaceutical Inc. (BMRN) is an American biopharmaceutical company specializing in the research, development, and manufacturing of drugs for rare genetic diseases and rare disorders. With a broad portfolio of medicines serving the needs of patients with genetically determined disorders, BioMarin is a leading innovator in the treatment of genetic diseases. The company is known for its pioneering therapeutic approaches and longstanding commitment to patients with rare diseases. BioMarin also actively invests in the research and development of new drugs and therapies to improve the quality of life for patients. BioMarin Pharmaceutical Inc. (BMRN) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on treating rare genetic diseases and innovative research and development.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Alexander Hardy

Employees

3,221

Headquarters

San Rafael

Prihajajoči dogodki

26 OKT.

Earnings

Upcoming earnings report

30d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.